Apr 18, 2023
|
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
|
Apr 13, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Apr 12, 2023
|
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
|
Mar 2, 2023
|
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
|
Feb 28, 2023
|
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
|
Feb 27, 2023
|
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
|
Feb 23, 2023
|
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
|
Feb 2, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Dec 29, 2022
|
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
|
Dec 23, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|